Moderna's Wild Ride: Stock Surges, Safety Scares, and Swings
Moderna's stock surged on promising new COVID vaccine data targeting the LP.8.1 variant, showing an eight-fold antibody boost in high-risk groups. Despite UBS maintaining a Buy rating, the stock remains volatile, down over 40% this year. Recent concerns linking COVID vaccines to child deaths, fueled by unfiltered federal data, have intensified investor jitters, overshadowing positive trial results and raising questions about future vaccine guidelines. Hosted on Acast. See acast.com/privacy for more information.